Treating Lipoprotein(a)-Hyperproteinemia and Progressive Cardiovascular Disease With Lipid-Apheresis in North America

Moriarty, Patrick M.; Minchew, Heather; Oktona, Donald C.

doi:10.1016/s0735-1097(18)32325-8

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is known that the elimination of fibrinogen (more than 60%) and large-molecular substances according to the lipid apheresis techniques affects the blood and plasma viscosity, rheological characteristics and aggregation properties of cells (erythrocytes, platelets) [37,38] . Terai et al [39] (2010) noted that changes of retina vessels' diameter are connected with systemic effect of LDL-apheresis, making basis for ocular perfusion improvement in the patients with hypercholesterolemia.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The use of lipoprotein apheresis for the treatment of high-risk patients with elevated lipoprotein(a) and hypercholesterolemia

Yaroustovsky¹,

Abramyan²,

Rogalskaya³

et al. 2019

View full text Add to dashboard Cite

Aim: To assess the safety and efficiency of H.E.L.P.-apheresis and cascade lipid-filtration in the treatment of severe lipid disorders in high-risk patients. Methods: From 2016 to 2018 we observed 6 patients hyperLDLemia and high Lp(a)emia (> 60 mg/dL). The first group with H.E.L.P.-apheresis (n = 74 sessions) included 3 patients who underwent revascularization (coronary, femoral arteries). In the second group with cascade lipid-filtration (n = 92 sessions)-one patients underwent revascularization, two patients received drug therapy. Despite the lipid-lowering conventional therapy, no targeted low density lipoprotein (LDL) was obtained. Results: The patients of the 1st group had threefold decrease of LDL, in patients of the 2nd group LDL decreased by 68%. At the same time, in both groups, we noted a decrease in Lp(a) after the procedure by 65%-68%. Despite a decrease in high density lipoprotein (by 22%-29%) after lipid apheresis procedures, there was a positive trend in apoB100/apoA index (a decrease of 33% after HELP-apheresis procedures and 60% after cascade lipid-filtration) and a decrease in atherogenic index (38% and 53%, respectively). The changes in hematological and haemostatic parameters remained within physiological intervals. Conclusion: We noticed the successful application of lipid apheresis in patients with multifocal atherosclerosis and its complications.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Statistically significant changes of hematological parameters after procedures were within or on the border of reference intervals. Taking into account the slight dynamics differences of the analytes measured between the sessions, the treatment is recommended to be individually choice to each patient's condition [38,45] .…”

Section: Discussionmentioning

confidence: 99%

The use of lipoprotein apheresis for the treatment of high-risk patients with elevated lipoprotein(a) and hypercholesterolemia

Yaroustovsky¹,

Abramyan²,

Rogalskaya³

et al. 2019

View full text Add to dashboard Cite

show abstract

Treating Lipoprotein(a)-Hyperproteinemia and Progressive Cardiovascular Disease With Lipid-Apheresis in North America

Cited by 1 publication

References 0 publications

The use of lipoprotein apheresis for the treatment of high-risk patients with elevated lipoprotein(a) and hypercholesterolemia

The use of lipoprotein apheresis for the treatment of high-risk patients with elevated lipoprotein(a) and hypercholesterolemia

Contact Info

Product

Resources

About